These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 38827323)
1. MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma: potential therapeutic targets and diagnostic/prognostic markers and web based tools. Shakiba E; Boroomand S; Kheradmand Kia S; Hedayati M Oncol Res; 2024; 32(6):1011-1019. PubMed ID: 38827323 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402 [TBL] [Abstract][Full Text] [Related]
3. MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives. Galuppini F; Censi S; Moro M; Carraro S; Sbaraglia M; Iacobone M; Fassan M; Mian C; Pennelli G Cells; 2021 Apr; 10(4):. PubMed ID: 33924120 [TBL] [Abstract][Full Text] [Related]
4. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817 [TBL] [Abstract][Full Text] [Related]
5. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2. Jiang M; Shi X; Zhu H; Wei W; Li J Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Abraham D; Jackson N; Gundara JS; Zhao J; Gill AJ; Delbridge L; Robinson BG; Sidhu SB Clin Cancer Res; 2011 Jul; 17(14):4772-81. PubMed ID: 21622722 [TBL] [Abstract][Full Text] [Related]
7. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker. Zhan S; Li J; Wang T; Ge W Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896 [TBL] [Abstract][Full Text] [Related]
8. Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. Titov SE; Demenkov PS; Ivanov MK; Malakhina ES; Poloz TL; Tsivlikova EV; Ganzha MS; Shevchenko SP; Gulyaeva LF; Kolesnikov NN Oncol Rep; 2016 Nov; 36(5):2501-2510. PubMed ID: 27666315 [TBL] [Abstract][Full Text] [Related]
9. miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8. Liu T; Meng J; Zhang Y Mol Med Rep; 2020 Oct; 22(4):3316-3326. PubMed ID: 32945439 [TBL] [Abstract][Full Text] [Related]
11. Identification of microRNAs associated with medullary thyroid carcinoma by bioinformatics analyses. Fu X; Fang J; Lian M; Zhong Q; Ma H; Feng L; Wang R; Wang H Mol Med Rep; 2017 Jun; 15(6):4266-4272. PubMed ID: 28487941 [TBL] [Abstract][Full Text] [Related]
12. A miRNA signature associated with human metastatic medullary thyroid carcinoma. Santarpia L; Calin GA; Adam L; Ye L; Fusco A; Giunti S; Thaller C; Paladini L; Zhang X; Jimenez C; Trimarchi F; El-Naggar AK; Gagel RF Endocr Relat Cancer; 2013 Dec; 20(6):809-23. PubMed ID: 24127332 [TBL] [Abstract][Full Text] [Related]
13. Identification and interaction analysis of key miRNAs in medullary thyroid carcinoma by bioinformatics analysis. Zhang L; Lu D; Liu M; Zhang M; Peng Q Mol Med Rep; 2019 Sep; 20(3):2316-2324. PubMed ID: 31322209 [TBL] [Abstract][Full Text] [Related]
14. Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples. Ciarletto AM; Narick C; Malchoff CD; Massoll NA; Labourier E; Haugh K; Mireskandari A; Finkelstein SD; Kumar G Cancer Cytopathol; 2021 Mar; 129(3):239-249. PubMed ID: 33017868 [TBL] [Abstract][Full Text] [Related]
15. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma. Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425 [TBL] [Abstract][Full Text] [Related]
16. Bioinformatics analyses of significant prognostic risk markers for thyroid papillary carcinoma. Min XS; Huang P; Liu X; Dong C; Jiang XL; Yuan ZT; Mao LF; Chang S Tumour Biol; 2015 Sep; 36(10):7457-63. PubMed ID: 25908172 [TBL] [Abstract][Full Text] [Related]
17. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834 [TBL] [Abstract][Full Text] [Related]
18. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. Karagiannis AK; Girio-Fragkoulakis C; Nakouti T Anticancer Res; 2016 Aug; 36(8):3803-10. PubMed ID: 27466480 [TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma. Weng D; He L; Chen X; Lin H; Ji D; Lu S; Ao L; Wang S Front Immunol; 2022; 13():1055412. PubMed ID: 36713370 [TBL] [Abstract][Full Text] [Related]
20. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer. Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]